Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 26 January 2012, 15:00 HKT/SGT
Share:
    

Source: A*STAR
Cambridge Team First to Grow Smooth Muscle Cells from Patient Skin Cells
A*STAR scholar Ms Christine Cheung first author of team paper published this month in Nature Biotechnology*

SINGAPORE, Jan 26, 2012 - (ACN Newswire) - A Cambridge University research team has for the first time discovered a method of generating different types of vascular smooth muscle cells (SMCs) - the cells which make up the walls of blood vessels - using cells from patients' skin. This work could lead to new treatments and better screening for cardiovascular disease.

Cardiovascular disease is the leading cause of death in the world**. These deaths are mainly caused by the hardening and subsequent blockage of blood vessels due to the accumulation of fatty materials, a condition called atherosclerosis. As not all patients are suitable for conventional stenting or bypass treatment, an option in the future may be to grow new blood vessels to bypass their own blocked vessels.

The team from Cambridge worked with embryonic stem cells and reprogrammed skin cells, collectively known as human pluripotent stem cells (hPSCs), which have the potential to form any cell type in the body. They discovered a method of creating all the major vascular smooth muscle cells in high purity using hPSCs which can also be easily scaled up for production of clinical-grade SMCs. This is the first time that such a system has been developed and will open the door for comparative studies on different subtypes of SMCs to be carried out, which are otherwise extremely difficult to obtain from patients.

The scientists created three subtypes of SMCs from different embryonic tissues which they reproduced in the culture dish and showed that the various SMC subtypes responded differently when exposed to substances that cause vascular diseases. They concluded that differences in the embryonic origin play a role in their susceptibility to diseases and may play a part in determining where and when common vascular diseases such as aortic aneurysms or atherosclerosis develop.

Dr Alan Colman, Principle Investigator of the Institute of Medical Biology under A*STAR and Executive Director of the Singapore Stem Cell Consortium, said, "This is a major advance in vascular disease modelling using patient-derived stem cells. The development of robust methods to make multiple, distinct smooth muscle subtypes provides tools for scientists to model and understand a greater range of vascular diseases in a culture dish than was previously available. It is a significant stride forward in being able to construct new blood vessels which will benefit a whole range of patients including those with cardiovascular diseases, renal failure and genetic disorders such as Marfans Syndrome that affect the normal function of their blood vessels."

Dr Lim Khiang Wee, Executive Director of the A*STAR Graduate Academy (A*GA), said, "Christine's work reflects the calibre of our scholars - they do excellent research and grow into scientists who will contribute to Singapore when they return."

Ms Christine Cheung is a National Science Scholarship (NSS) scholar and is doing her final year PhD studies at Cambridge University (UK). The NSS scholarship is one of the programmes offered by A*GA, to attract and develop outstanding young talent passionate about research who will spearhead Singapore's drive to becoming Asian's Innovation Capital.

* The paper "Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility" was published on Nature Biotechnology's website on 15 January. Ms Christine Cheung is funded by a National Science Scholarship from the A*STAR (Agency for Science, Technology and Research, Singapore). The other authors are Dr Andreia S Bernardo, Dr Matthew W B Trotter, Prof Roger A Pedersen & Dr Sanjay Sinha (Christine's PhD supervisor). Additional funding was provided by the Wellcome Trust and the Medical Research Council. http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.2107.html

** http://www.who.int/mediacentre/factsheets/fs317/en/index.html


Contact:
Ms Ong Siok Ming 
Senior Officer, Corporate Communications 
Agency for Science, Technology and Research 
Tel: +65 6826 6254 
Email: ong_siok_ming@a-star.edu.sg


Topic: General Announcement
Source: A*STAR

Sectors: Science & Research, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



A*STAR
Dec 6, 2022 14:00 HKT/SGT
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
June 2, 2022 21:00 HKT/SGT
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies
June 2, 2022 21:00 HKT/SGT
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies
Sept 30, 2021 16:00 HKT/SGT
A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes
July 31, 2020 08:00 HKT/SGT
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials
July 24, 2020 17:00 HKT/SGT
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2
Oct 22, 2019 04:00 HKT/SGT
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology
June 28, 2019 08:00 HKT/SGT
Singapore's Drug Development Efforts Given Additional Momentum with National Platforms
Apr 5, 2019 18:00 HKT/SGT
Passing of Dr Sydney Brenner, Nobel Laureate, Renowned Pioneer in Molecular Biology, A*Star Senior Fellow
Jan 21, 2019 13:00 HKT/SGT
Branched-Chain Amino Acids Found to Regulate the Development and Progression of Cancer
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: